Johannes F. Dayrit MD,Audi Sugiharto MD,Sarah J. Coates MD,Don Eliseo Lucero-Prisno III MD, PhD,Mark Denis D. Davis MD,Louise K. Andersen MD
doi : 10.1111/ijd.15543
Volume 61, Issue 2 p. 127-138
Climate change, exemplified by higher average global temperatures resulting in more frequent extreme weather events, has the potential to significantly impact human migration patterns and health. The consequences of environmental catastrophes further destabilize regions with pre-existing states of conflict due to social, political, and/or economic unrest. Migrants may carry diseases from their place of origin to their destinations and once there may be susceptible to diseases in which they had not been previously exposed to. Skin diseases are among the most commonly observed health conditions observed in migrant populations. To improve awareness among dermatologists of the burden of skin diseases among migrants, the group searched the English language scientific literature to identify articles linking climate change, migration, and skin disease. Skin diseases associated with human migration fall into three major categories: (i) communicable diseases, (ii) noncommunicable diseases, and (iii) environmentally mediated diseases. Adopting comprehensive global strategies to improve the health of migrants requires urgent attention.
Christine E. Jo BSc,Melinda Gooderham MD, MSc, FRCPC,Jennifer Beecker MD, CCFP(EM), FRCPC, FAAD
doi : 10.1111/ijd.15605
Volume 61, Issue 2 p. 139-147
Increasing understanding of cytokines as major drivers of immune-mediated diseases has revolutionized targeted treatments for these conditions. As the pathogenesis of autoimmune conditions is mediated by a complex interplay of various cytokines, Janus kinase (JAK) inhibitors have been of particular interest due to their ability to target multiple cytokines simultaneously. However, due to safety concerns with first generation JAK inhibitors, most notably from JAK2 and JAK3 inhibition, interest has shifted to more selective inhibition of TYK2. Three key TYK2 inhibitors that have advanced furthest in clinical trials for treatment of dermatologic autoimmune conditions are deucravacitinib (BMS-986165), brepocitinib (PF-06700841), and PF-06826647. This review outlines the current understanding of the efficacy and safety of these three TYK2 inhibitors from completed phase I and II studies and summarizes studies currently in progress for dermatologic conditions.
Johannes Kjeldstrup Kristensen MD, DMSc,Corina Nielsen MSc
doi : 10.1111/ijd.15654
Volume 61, Issue 2 p. 148-157
Hyperhidrosis is excessive sweating that is uncontrollable and occurring regardless of temperature. Quality of life is significantly impaired, and psychiatric comorbidity is common. The objective of the study is to undertake a systematic review of research in the last 5?years regarding hyperhidrosis. Five databases were searched from July 2015 to July 2020 for all research on hyperhidrosis. High-quality research articles were sought for progress in diagnosis, etiology and epidemiology, and use of patient reported outcomes (PROs) as well as randomized clinical trials (RCTs) on any treatment intervention. Outcomes of interest were disease severity, sweat rate, quality of life, patient satisfaction, and adverse events. Trial quality was assessed by the Cochrane risk-of-bias tool. A narrative synthesis was presented. Twenty-nine papers were included in the review: 13 investigational articles, 10 RCTs, three cohort studies, and three reviews. The studies varied in terms of quality, population, intervention, and methods of outcome assessment. The majority were very small studies, and most RCTs were at high risk of bias. Few studies on diagnosis, epidemiology, and etiology were of sufficient quality to be presented. The interventions discussed were iontophoresis, botulinum toxin, anticholinergic medication, curettage, and energy-based technologies. Progress in the diagnostics and etiology of hyperhidrosis is limited with the same being true for treatment. In a 5-year-old systematic review, it was concluded that there was moderate-quality evidence to support the use of botulinum toxin for axillary hyperhidrosis. It was advocated to conduct a trial comparing BTX and iontophoresis for palmar hyperhidrosis. Unfortunately, this has not yet been performed. Hyperhidrosis is still as underserved and under-studied as before.
Carly A. Crowder MD,Sarah E. S. Jeney MD,Christina N. Kraus MD,Nicole Bernal MD,Felicia Lane MD
doi : 10.1111/ijd.15676
Volume 61, Issue 2 p. 158-163
Vulvovaginal involvement in Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is common, likely underdiagnosed, and can result in severe sequelae if not managed acutely. There are few studies on acute management of vulvovaginal SJS/TEN. Current recommendations are predominantly based on expert opinion. We aimed to determine the frequency of vulvovaginal involvement in SJS/TEN at a single institution, identify treatment modalities, and assess outcomes at a tertiary care burn center.
Eleonora Farinazzo MD,Enrico Zelin MD,Claudio Conforti MD,Vittorio Ramella MD,Rossana Bussani MD,Iris Zalaudek MD,Nicola Di Meo MD
doi : 10.1111/ijd.15709
Volume 61, Issue 2 p. 164-166
Lilian K. F. L. Rocha MD,Ricardo E. Vilain PhD,Richard A. Scolyer BMedSci, MBBS,Serigne N. Lo PhD,Martin Drummond MS,Phoebe Star MBBS, BSci,Gerald B. Fogarty MBBS, PhD,Angela M. Hong MBBS MMed, PhD, FRANZCR,Pascale Guitera PhD, FACD
doi : 10.1111/ijd.15815
Volume 61, Issue 2 p. 167-174
Atypical intraepidermal melanocytic proliferations (AIMP) is a descriptive term sometimes applied to biopsies that do not fulfill diagnostic criteria of melanoma. They are common on sun-damaged skin, but their definition and management are controversial.
Cosimo Di Raimondo MD,Raffaele Dante Caposiena Caro MD,Diana Spallone MD,Dionisio Silvaggio MD,Paolo Lombardo MD,Ester Del Duca MD,Elena Campione MD, PhD,Giulia Spallone MD,Luca Bianchi MD
doi : 10.1111/ijd.15755
Volume 61, Issue 2 p. 175-179
The neutrophil/lymphocyte ratio (NLR) and red blood cell distribution width (RDW) at diagnosis have been shown to correlate with advanced disease and to be prognostic factors in many tumors. However, their role as a prognostic factor for cutaneous squamous cell carcinoma (cSCC) has not yet been studied.
Gerardo Gilligan DDS, PhD,Nicolás Leonardi DDS,Federico Garola DDS,Agustina Sanfedele BDS,Agostina Beltramo BDS,René Panico DDS, PhD,Eduardo Piemonte DDS, PhD
doi : 10.1111/ijd.15787
Volume 61, Issue 2 p. 180-183
Syphilis is the oldest sexually transmitted infectious disease in humanity. In the last decades, it was noted the re-emergence of the disease, and actually it remains an important public health problem. Oral mucosa could be affected by the infection. Oral manifestations are commonly associated with secondary syphilis. It was described that the labial commissure could be involved as a split papule, also known as false cheilitis (FC). However, this clinical manifestation is poorly described in current literature.
Christina S. M. Wong MBBS, MRCP(UK), MSc (London) FHKAM (Medicine), FHKCP,Desmond Y. H. Yap MBBS, MD, PhD,Patrick Ip MBBS, FRCPCH, FHKAM (Paed), FHKCPaed, PhD,Wilfred H. S. Wong PhD,Gilbert T. Chua MBBS, MRCPCH (UK), FHKCPaed, FHKAM (Paed),Chi-Keung Yeung MBBS, MD, FRCP,Henry H. L. Chan MBBS, MD, PhD, FRCP,Janette S. Y. Kwok MBBS, FRCPA, FHKCPath, FHKAM (Pathology), PhD
doi : 10.1111/ijd.15792
Volume 61, Issue 2 p. 184-190
HLA-B*15:11 is associated with carbamazepine (CBZ)-induced severe cutaneous adverse drug reactions (SCARs) in Japanese and some Asian populations, but such data remains relatively limited in Chinese. Routine HLA-B*15:02 screening is mandatory before CBZ commencement, however, SCARs related to CBZ were still observed in non-HLA*B-15:02 carriers.
Flavia Franco Veiga MD,Lidiane Vizioli de Castro-Hoshino PhD,Francielle Sato PhD,Mauro Luciano Baesso PhD,Sónia Silva PhD,Melyssa Negri PhD,Terezinha Inez Estivalet Svidzinski PhD
doi : 10.1111/ijd.15747
Volume 61, Issue 2 p. 191-198
Fusarium spp. has been considered as an onychomycosis agent, but little is known about the etiopathogenesis of fusarial onychomycosis; thus, the objective of this study was to characterize the fungal-nail interaction and the consequences of the nail infection process by Fusarium oxysporum using the human nail, in an ex vivo model.
Maha Alhelf MD,Laila A. Rashed MD,Noura Ragab MSc,Maha F. Elmasry MD
doi : 10.1111/ijd.15669
Volume 61, Issue 2 p. 199-207
Taurine-upregulated gene 1 (TUG1) is one of the long noncoding RNAs (lncRNAs) that plays a role in melanogenesis. MicroRNA-377 (miRNA-377) is a conserved noncoding RNA that regulates angiogenesis and promotes oxidative stress. Peroxisome proliferator-activated receptors (PPARs) are components of the nuclear hormone receptor superfamily. PPAR-? activators stimulate melanogenesis. Interleukin (IL)-17 has been implicated in the pathogenesis of several immunological diseases. This work aimed at detecting the expression levels of lncRNA TUG1, miRNA-377, PPAR-?, and IL-17 among vitiligo subjects and to investigate their possible role in the pathogenesis of vitiligo.
Ayelet Rishpon MD,Eli Sprecher MD, PhD,Stephen W. Dusza DrPH,Elana Kleinman BS,Sara Haupt PhD,Harold Rabinovitz MD,Alon Scope MD
doi : 10.1111/ijd.15754
Volume 61, Issue 2 p. 208-215
The morphology of benign pigmented lesions on the ears has been scarcely studied.
Husein Husein-ElAhmed MD, PhD,Martin Steinhoff MD, PhD
doi : 10.1111/ijd.15680
Volume 61, Issue 2 p. 216-225
The current scenario and position of laser and light-based therapies (LLBT) in the therapeutic rosacea scheme are lacking evidence-based recommendations and comparisons on efficacy and tolerability among different devices. This article aimed to systematically compare the efficacy, acceptability, and tolerability of the pulsed dye laser (PDL) versus other devices.
Collin M. Costello MD,Jamison A. Harvey MD,Jake G. Besch-Stokes BS,Puneet Bhullar BS,Elisabeth S. Lim MPH,Katie L. Kunze PhD,Megha M. Tollefson MD,Leila M. Tolaymat MD,Shari A. Ochoa MD
doi : 10.1111/ijd.15964
Volume 61, Issue 2 p. 226-230
A new trend includes taking a dedicated year away from medical school to complete a research fellowship. There is minimal data on the benefit of a gap year. We aimed to identify if a gap year makes a dermatology applicant more successful in The Match.
Tatiana Mina Yendo MD,Denise Miyamoto MD, PhD,Cláudia G. Santi MD, PhD
doi : 10.1111/ijd.15819
Volume 61, Issue 2 p. 231-233
Gautam K. Singh MD,Sandeep Arora MD,Pankaj Das MD,Arun R. John MD,Akanksha Gupta MD
doi : 10.1111/ijd.15951
Volume 61, Issue 2 p. 234-237
Kevin Brough MD,Sama K. Carley MD,Nahid Y. Vidal MD
doi : 10.1111/ijd.15847
Volume 61, Issue 2 p. 238-245
Although most cases of extramammary Paget's disease (EMPD) are localized to the intraepidermal, the extensive subclinical extension can lead to high rates of marginal recurrence with wide local excisions and topically destructive treatments. Recurrence rates of EMPD treated with Mohs micrographic surgery (MMS) without immunohistochemical staining are better but variable. Here, we describe our multidisciplinary approach for treating large EMPD tumors of the anogenital region involving critical anatomy using MMS for peripheral margin clearance (moat method) and intraoperative CK7 immunostaining. Our clinical pearls for the management of anogenital EMPD are based on 53 multidisciplinary cases treated at the author's institution between 2014 and 2020.
Chaodi Huang MD,Jianping Tang MD, PhD
doi : 10.1111/ijd.15977
Volume 61, Issue 2 p. 246-251
We evaluated the clinical effect and safety of sublingual immunotherapy (SLIT) with Dermatophagoides farinae drops for pediatric atopic dermatitis (AD).
Yu Cui MM,Caixia Hu MM,Yi Cheng MM,Xiaomei Han MM,Wenqing Wang MD
doi : 10.1111/ijd.15892
Volume 61, Issue 2 p. 252-256
Bullous pemphigoid (BP) patients were vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection because they have similar risk factors, so we should pay attention to patients with BP during the epidemic of coronavirus disease-19 (COVID-19). As far as treatment is concerned, many strategies for BP were changed during the epidemic. Plasmapheresis not only has been included in the guidelines for BP but also has been used successfully to rescue COVID-19 patients, especially in severe cases. Therefore, it is a feasible choice for BP patients, especially for refractory BP patients, infected with SARS-CoV-2. Apart from these, we have reviewed some points for attention during the plasmapheresis session.
Ngo Binh Trinh MD,Giang Huong Tran MD, PhD
doi : 10.1111/ijd.15772
Volume 61, Issue 2 p. e43-e44
Valencia Long MRCP, MMed (IM),Chris Lixian Tan MBBS, FAMS,Ellie Ci-En Choi MRCP, MMed (IM)
doi : 10.1111/ijd.15662
Volume 61, Issue 2 p. e44-e46
Sumir Chawla MD,Alex Gan MD,Rathi Ramakrishnan MD,Richard Watchorn MD,Neil P. Patel MD, PhD
doi : 10.1111/ijd.15907
Volume 61, Issue 2 p. e46-e47
Rym Afiouni MD,Reine Merhy MD,Samer Ghosn MD,Roland Tomb MD, PhD,Maya Halabi-Tawil MD
doi : 10.1111/ijd.15827
Volume 61, Issue 2 p. e47-e49
Miguel Alpalhão MD,Luís Marques-Lito MD,Paulo Filipe MD, PhD,João Borges-Costa MD, PhD
doi : 10.1111/ijd.15769
Volume 61, Issue 2 p. e49-e50
Cláudio de Lélis Filgueiras de Souza MD, MSc,Guilherme Gonçalves Nascimento MD,João Paulo de Oliveira MD,Júlia Carvalho Giannini MD,Roberta Bessa de Veloso Silva MSc, PhD,Adilson da Costa MD, MSc, PhD
doi : 10.1111/ijd.15674
Volume 61, Issue 2 p. e50-e52
Camille Grodner MD,Charlotte Bernigaud MD, PhD,Simone Lapadula MD,Helene Beringuer MD,Pierre-Antoine Billiet MD,Paul-Louis Woerther MD,Raphaelle Billon MD,Henri Derhy MD,Benjamin Haye MD,Claire Hotz MD,Claire Pressiat MD,Dominique Vodovar MD,Christophe Rodriguez MD,Nicolas Fabresse MD,Nicolas de Prost PhD,Camille Hua MD,Oliver Chosidow PhD,Henri Mondor Hospital Necrotizing Fasciitis Group
doi : 10.1111/ijd.15818
Volume 61, Issue 2 p. e52-e54
Yng Sun MD,Stephen Chu-Sung Hu MBBS, MPhil
doi : 10.1111/ijd.15841
Volume 61, Issue 2 p. e54-e55
Sambasiviah C. Murthy MD,Megha Shankar MBBS
doi : 10.1111/ijd.15610
Volume 61, Issue 2 p. e56-e58
Antonella Tammaro MD,Ganiyat A. R. Adebanjo MD,Francesca Magri MD,Francesca R. Parisella MD,Gabriella De Marco MD
doi : 10.1111/ijd.15622
Volume 61, Issue 2 p. e58-e59
Ryotaro Torai MD,Teruhiko Makino MD, PhD,Yu Matsui MD,Tadamichi Shimizu MD, PhD
doi : 10.1111/ijd.15639
Volume 61, Issue 2 p. e59-e61
Yoon-Seob Kim MD,Seung-Hyun Jung PhD,Yeun-Jun Chung MD, PhD,Ji Hyun Lee MD, PhD
doi : 10.1111/ijd.15766
Volume 61, Issue 2 p. e61-e63
Jon Fulgencio-Barbarin MD,Ángela Manzanares MD,Jose Luis Rodriguez-Peralto PhD,Alba Calleja-Algarra MD
doi : 10.1111/ijd.15620
Volume 61, Issue 2 p. e63-e65
Ömer Kutlu MD, MRCP, EBDV
doi : 10.1111/ijd.15783
Volume 61, Issue 2 p. e65-e67
Anissa Zaouak MD,Mouna Daldoul MD,Amal Chamli MD,Ehsen Ben Brahim MD,Samy Fenniche MD,Houda Hammami MD
doi : 10.1111/ijd.15789
Volume 61, Issue 2 p. e67-e69
Bryan Moore BS,Abigail Washington BA,Melissa Butt MPH,Colleen Silva MD,Brian Green DO,Matthew Helm MD
doi : 10.1111/ijd.15618
Volume 61, Issue 2 p. e69-e71
Fernanda Ayres de Morais e Silva Cardoso MD, MSc,Rafael de Deus Moura MD,Emily Ferreira Salles Pilar BS, PhD,Isabel Cristina Gomes Moura PhD,Hélio Amarante Miot MD, PhD,Adilson da Costa MD, MSc, PhD
doi : 10.1111/ijd.15720
Volume 61, Issue 2 p. e71-e74
Sabah Osmani BA,Zefr Chao MD,Raymond Barnhill MD,Marianne Berwick PhD
doi : 10.1111/ijd.15621
Volume 61, Issue 2 p. e74-e76
Farzana Ansari MD, DNB,Ravikumar Mudugal SM, MD, DNB,Saurabh Singh MD, DNB,Sushma Bharti MD,Jyotsna N. Bharti MD,Asma Nalwa MD
doi : 10.1111/ijd.15711
Volume 61, Issue 2 p. e76-e79
Graziella Babino MD,Ilenia D’Ambra MD,Elisabetta Fulgione MD,Roberto Alfano MD, PhD,Pasquale Verolino MD,Giuseppe Argenziano MD, PhD
doi : 10.1111/ijd.15730
Volume 61, Issue 2 p. e79-e80
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟